ArticleJournal of Korean medical science2024

Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea.

Eui-Soon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.